

Application No. 08/819,669

Docket No.: NY-LUD 5253-US5-DIV

Reply to Final Office Action of July 7, 2009

## AMENDMENTS TO THE CLAIMS

Claims 1-182 (Canceled)

183. (Previously presented) An isolated, MAGE tumor rejection antigen precursor protein, wherein said protein is encoded by a nucleic acid molecule, the complementary sequence of which hybridizes to SEQ ID NO: 8 at 0.1xSSC, 0.1% SDS, wherein said tumor rejection antigen precursor is obtainable from melanoma cells.

184. (Previously presented) The isolated tumor rejection antigen precursor protein of claim 183, the amino acid sequence of which comprises the amino acid sequence set forth in SEQ ID NO: 26.

185. (Previously presented) The isolated tumor rejection antigen precursor protein of claim 183, wherein said protein is a human protein.

186. (Previously presented) Composition comprising the isolated tumor rejection antigen precursor protein of claim 183, and a pharmaceutically appropriate ingredient.

187. (Previously presented) Composition comprising the isolated tumor rejection antigen precursor protein of claim 184, and a pharmaceutically appropriate ingredient.

188. (Previously presented) Composition comprising the isolated tumor rejection antigen precursor protein of claim 185, and a pharmaceutically appropriate ingredient.

Application No. 08/819,669

Docket No.: NY-LUD 5253-US5-DIV

Reply to Final Office Action of July 7, 2009

189. (Previously presented)

The composition of claim 186, in the form of a vaccine.

190. (Previously presented)

The composition of claim 187, in the form of a vaccine.

191. (Previously presented)

The composition of claim 188, in the form of a vaccine.

192. (Currently amended)

The isolated MAGE tumor rejection antigen precursor protein of claim 183, wherein said protein is encoded by a nucleic acid molecule, the complementary sequence of which hybridizes to SEQ ID NO: 8 at 0.1xSSC, 0.1% SDS, wherein said tumor rejection antigen precursor is obtainable from melanoma cells and has an amino acid sequence encoded by a nucleotide sequence set forth in SEQ ID NO: 9, 11, or 13.

193. (Previously presented)

The isolated tumor rejection antigen precursor of claim 192, wherein said nucleotide sequence is set forth in SEQ ID NO: 9.

194. (Previously presented)

The isolated tumor rejection antigen precursor of claim 192, wherein said nucleotide sequence is set forth in SEQ ID NO: 11.

195. (Previously presented)

The isolated tumor rejection antigen precursor of claim 192, wherein said nucleotide sequence is set forth in SEQ ID NO: 13.